TWI718100B - Positive pressure capsule and manufacturing method thereof - Google Patents
Positive pressure capsule and manufacturing method thereof Download PDFInfo
- Publication number
- TWI718100B TWI718100B TW104125059A TW104125059A TWI718100B TW I718100 B TWI718100 B TW I718100B TW 104125059 A TW104125059 A TW 104125059A TW 104125059 A TW104125059 A TW 104125059A TW I718100 B TWI718100 B TW I718100B
- Authority
- TW
- Taiwan
- Prior art keywords
- capsule
- positive pressure
- item
- patent application
- gelatin
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 130
- 238000004519 manufacturing process Methods 0.000 title abstract description 9
- 108010010803 Gelatin Proteins 0.000 claims abstract description 28
- 239000008273 gelatin Substances 0.000 claims abstract description 28
- 229920000159 gelatin Polymers 0.000 claims abstract description 28
- 235000019322 gelatine Nutrition 0.000 claims abstract description 28
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 28
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 15
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000000945 filler Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 6
- 239000007789 gas Substances 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000004014 plasticizer Substances 0.000 claims description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000000475 sunscreen effect Effects 0.000 claims description 6
- 239000000516 sunscreening agent Substances 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000004804 polysaccharides Chemical class 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 229940023476 agar Drugs 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 235000013736 caramel Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 18
- 239000007902 hard capsule Substances 0.000 abstract description 6
- 238000007789 sealing Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- -1 alkoxy anion Chemical class 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241001474374 Blennius Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940121383 antituberculosis agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000000451 gelidium spp. gum Substances 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ZFACJPAPCXRZMQ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O.OC(=O)C1=CC=CC=C1C(O)=O ZFACJPAPCXRZMQ-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- 229940126589 solid medicine Drugs 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
本發明係關於一種正壓膠囊及其製造方法,係包括於膠囊開口處注入填充物(如藥物),並將膠囊密封、內部含有氣體空間形成正壓膠囊。該正壓膠囊之特徵為密合接縫以及可充填液態粉末等填充物,該膠囊可為硬膠囊,原料可為明膠(gelatin)或羥丙基甲基纖維素(HPMC)。 The present invention relates to a positive pressure capsule and a manufacturing method thereof. The positive pressure capsule is formed by injecting fillers (such as drugs) into the opening of the capsule, sealing the capsule and containing a gas space inside. The positive pressure capsule is characterized by tight seams and filling with liquid powder and other fillers. The capsule can be a hard capsule, and the raw material can be gelatin or hydroxypropyl methylcellulose (HPMC).
Description
本發明係關於一種正壓膠囊及其製造方法,該正壓膠囊可加快破壞膠囊形成破口以及加速填充物(如藥物)釋放,該膠囊之特徵為密封膠囊內含有氣體,且內部壓力為正壓。 The present invention relates to a positive pressure capsule and a manufacturing method thereof. The positive pressure capsule can accelerate the destruction of the capsule to form a rupture and accelerate the release of the filling material (such as medicine). The characteristic of the capsule is that the sealed capsule contains gas and the internal pressure is positive. Pressure.
膠囊是一種發展迅速的藥物劑型,厚度約略為0.1-0.7毫米,廣泛應用到醫藥、保健食品等內服藥物,具有方便保存、劑量準確、可控制藥物釋放等優點,且可掩蓋藥物活性成分的不良氣味、維持藥物活性,因此服用者易於接受。 Capsule is a rapidly developing pharmaceutical dosage form with a thickness of about 0.1-0.7 mm. It is widely used in medicines, health foods and other internal medicines. It has the advantages of convenient storage, accurate dosage, controllable drug release, etc., and can cover up the defects of the active ingredients of the drug. Odor and maintain the activity of the drug, so it is easy for users to accept.
膠囊劑型可將填充物封存於膠囊內部,由於其密封的特徵,膠囊其中的藥物可避免因與外界空氣、水分接觸而降低活性或受潮,因此保持長期穩定。 The capsule dosage form can seal the filling inside the capsule. Due to its sealing feature, the medicine in the capsule can avoid the decrease in activity or moisture due to contact with the outside air and moisture, so it remains stable for a long time.
某些藥用活性物質可能具有使其難以配製成商業上可接受的配方的生物藥學或物理化學性質。然而,這樣的物質可以以液體載體介質形式給藥。1,2-丙二醇(1,2-propanediol)和二甲基異山梨糖醇酐(dimethylisosorbide)作為溶劑用於這樣的載體介質的潛力很大。載體介質的組成可使其在胃中形成乳液,因而促進藥用活性物質的吸收。載體介質必須準確地製備,從而使其不對藥物成分產生影響,並且不會破壞其有益的 性質。藥物載體的增溶性質可能改變活性物質性質使之沈澱,造成患者用藥量就不足。藥物載體的乳化(emulsifying)性質也可改變,並且給藥時在胃中可能不形成乳液(emulsion),並且藥學活性物質不會被正確地吸收。 Certain pharmaceutically active substances may have biopharmaceutical or physicochemical properties that make it difficult to formulate into commercially acceptable formulations. However, such substances can be administered in the form of a liquid carrier medium. 1,2-propanediol (1,2-propanediol) and dimethylisosorbide (dimethylisosorbide) as solvents have great potential for such carrier media. The composition of the carrier medium allows it to form an emulsion in the stomach, thus facilitating the absorption of the medicinal active substance. The carrier medium must be accurately prepared so that it does not affect the composition of the drug and does not destroy its beneficial nature. The solubilizing properties of the drug carrier may change the properties of the active substance and cause it to precipitate, resulting in insufficient dosage for the patient. The emulsifying properties of the drug carrier may also be changed, and an emulsion may not be formed in the stomach during administration, and the pharmaceutically active substance may not be properly absorbed.
這種液體配方封裝在膠囊中為這種藥用活性物質提供了一種非常方便的給藥方法。然而,商業上可接受的填充液禮的膠囊製品也伴隨有限制該途徑可用性的困難。 This liquid formula encapsulated in a capsule provides a very convenient method of administration for this medicinal active substance. However, commercially acceptable liquid-filled capsule products are also accompanied by difficulties that limit the availability of this approach.
用於醫藥之膠囊可分為硬式膠囊與軟式膠囊兩類,其中硬式膠囊(以下簡稱硬膠囊)可填充藥粉或細顆粒藥物等固態藥物,軟式膠囊(以下簡稱軟膠囊)可填充藥水等液態藥物。 Capsules used in medicine can be divided into hard capsules and soft capsules. Hard capsules (hereinafter referred to as hard capsules) can be filled with solid medicines such as powder or fine particles, and soft capsules (hereinafter referred to as soft capsules) can be filled with liquid medicines such as liquid medicine. .
膠囊原料可為明膠(gelatin)、山梨醇(sorbital)、羥丙基甲基纖維素(hydroxypropyl methylcellulose,縮寫作HPMC)以及不透明食用色素或其他添加物。 The capsule materials can be gelatin, sorbital, hydroxypropyl methylcellulose (HPMC), opaque food coloring or other additives.
傳統膠囊製造原料為明膠(gelatin),係自動物表皮、骨、或結締組織所萃取之蛋白質或胜肽,內涵膠原(collagen),在水中煮沸之後可得親水性淡黃色之蛋白質層,即為明膠。 The raw material for traditional capsule manufacturing is gelatin, which is a protein or peptide extracted from the epidermis, bone, or connective tissue of animals, and contains collagen. After boiling in water, a hydrophilic, light yellow protein layer can be obtained, which is gelatin.
另經常使用之膠囊原料可為羥丙基甲基纖維素,亦有簡化作羥丙甲纖維素(hydroxypropyl methylcellulose,縮寫作HPMC),是一種具有黏性的聚合物,常於在口服藥物中充當賦型劑、乳化劑、增稠劑、懸浮劑或明膠的替代品。纖維素用鹼處理後,羥基去質子化生成的烷氧負離子可對環氧丙烷進行加成,生成羥丙基纖維素醚;也可以與氯甲烷縮合,生成甲基纖維素醚。兩種反應同時進行時便會產生羥丙基甲基纖維素。 Another frequently used capsule material can be hydroxypropyl methylcellulose, which is also simplified as hydroxypropyl methylcellulose (HPMC). It is a viscous polymer that is often used in oral medicines. Excipients, emulsifiers, thickeners, suspending agents or alternatives to gelatin. After the cellulose is treated with alkali, the alkoxy anion generated by the deprotonation of the hydroxyl group can be added to propylene oxide to form hydroxypropyl cellulose ether; it can also be condensed with methyl chloride to form methyl cellulose ether. When the two reactions proceed simultaneously, hydroxypropyl methylcellulose is produced.
另有多種膠囊原料之替代物,包括海藻的萃取物即多醣膠 體為替代原料,植物性原料可避免與膠囊內含之動物性蛋白發生交聯反應,可維持膠囊囊體的強度,且因為近年美國狂牛病之流行漸起,改良軟膠囊原料逐漸受到重視。其他替代原料,如瓊脂膠、水溶性醚化澱粉衍生物、HPMC、即角叉菜膠等,也逐漸具有市占率。 There are also many alternatives to capsule raw materials, including seaweed extracts or polysaccharide gums As an alternative raw material, plant-based raw materials can avoid cross-linking reaction with the animal protein contained in the capsule, and can maintain the strength of the capsule body. Because of the increasing popularity of mad cow disease in the United States in recent years, improved soft capsule raw materials have gradually received attention . Other alternative raw materials, such as agar gum, water-soluble etherified starch derivatives, HPMC, carrageenan, etc., have gradually gained market share.
膠囊改良之目的,其中之一係為改善醫藥藥劑的生物利用率。活性成分可在膠囊破裂之時就以液體形式快速釋出。和錠劑組合物不同的是,要讓活性成分變成可吸收之狀態,並不需要膠囊完全崩解。同時,相較之下不可溶之活性成分可散布在液體載劑中以提供較快速之吸收,如疏水性藥物在親水性溶劑中之溶液;在消化作用中,膠囊會在胃中破裂,而疏水性藥物可散布於胃液。 One of the purposes of capsule improvements is to improve the bioavailability of pharmaceuticals. The active ingredient can be quickly released in liquid form as soon as the capsule is ruptured. Unlike the tablet composition, it is not necessary for the capsule to disintegrate completely in order for the active ingredient to become an absorbable state. At the same time, relatively insoluble active ingredients can be dispersed in a liquid carrier to provide faster absorption, such as a solution of a hydrophobic drug in a hydrophilic solvent; during digestion, the capsule will burst in the stomach, and Hydrophobic drugs can be dispersed in the gastric juice.
但膠囊在崩解的過程中有遲緩現象是常見問題,研究認為膠囊崩解遲緩主要是由於明膠產生交聯反應所致。由於明膠分子中氨基酸易發生氧化而形成醛基,形成的醛基可以與周圍氨基酸發生交聯反應,從而形成分子內/間相互聯結的三維網狀結構,導致明膠分子量、結構穩定度增加、水溶性下降,造成膠囊的崩解遲緩。針對膠囊崩解的問題,主要解決方法有:1.加入抗氧化劑、2.調整膠囊配方及改變成分如水、增塑劑等比例、3.採用較不容易氧化的原料。 However, it is a common problem that capsules are slow in the process of disintegration. Studies believe that the slow disintegration of capsules is mainly caused by the cross-linking reaction of gelatin. Since the amino acids in the gelatin molecule are prone to oxidation to form aldehyde groups, the formed aldehyde groups can undergo cross-linking reactions with surrounding amino acids to form a three-dimensional network structure of intramolecular/intermolecular interconnection, resulting in increased gelatin molecular weight, structural stability, and water solubility Decreased sex, resulting in slow disintegration of the capsule. To solve the problem of capsule disintegration, the main solutions are: 1. Add antioxidant, 2. Adjust capsule formula and change the proportion of ingredients such as water and plasticizer, 3. Use raw materials that are less prone to oxidation.
為解決前述膠囊不易崩解,而影響藥物於胃液中之生物利用率之缺點,發明人費心構想研發而得本發明內容。 In order to solve the aforementioned shortcomings that the capsule is not easy to disintegrate and affect the bioavailability of the drug in the gastric juice, the inventor has bothered to devise and develop the present invention.
為達前述之發明目的,本發明提供一正壓膠囊,係利用膠囊內部壓力為正壓之特性,經服用後加速膠囊於胃中破壞及崩解的速度, 進而加速填充物(如藥物)之釋放,以利填充物吸收,被生物體所利用。 In order to achieve the above-mentioned purpose of the invention, the present invention provides a positive pressure capsule, which utilizes the characteristic of the internal pressure of the capsule to be positive pressure to accelerate the destruction and disintegration of the capsule in the stomach after being taken. This speeds up the release of fillers (such as drugs) to facilitate the absorption of fillers and use them by organisms.
其中,該膠囊可為密封膠囊。 Wherein, the capsule may be a sealed capsule.
其中,該膠囊內部壓力須為正壓,且大於一大氣壓。 Among them, the internal pressure of the capsule must be positive pressure and greater than one atmosphere.
其中,該膠囊內部含有氣體,該氣體可為氧氣、氦氣、氮氣、或二氧化碳或上述氣體之混和氣體。 Wherein, the capsule contains gas, and the gas can be oxygen, helium, nitrogen, or carbon dioxide or a mixture of the above gases.
其中,該膠囊原料可為明膠,即產生於動物性膠原蛋白之水解物。 Wherein, the raw material of the capsule can be gelatin, which is a hydrolysate of animal collagen.
其中,該膠囊原料可為羥丙甲纖維素(hydroxypropyl methylcellulose,HPMC)。 Among them, the capsule material can be hydroxypropyl methylcellulose (HPMC).
其中,該膠囊原料可進一步包括洋菜、澱粉、藻酸、瓜爾膠(guar gum),以及藥學上可接受之遮光劑、可塑劑等添加劑。 Among them, the capsule material may further include agar, starch, alginic acid, guar gum, and pharmaceutically acceptable additives such as sunscreens and plasticizers.
其中,該明膠可為鹼處理明膠、酸處理明膠、或化學修飾(chemical modification)明膠等。 Wherein, the gelatin may be alkali-treated gelatin, acid-treated gelatin, or chemically modified gelatin.
其中,該可塑劑係可選自以下所組成之群組:甘油、山梨糖醇、麥芽糖、葡萄糖、多糖、蔗糖、木糖醇、甘露糖醇、丙二醇、聚乙二醇。 Wherein, the plasticizer can be selected from the group consisting of glycerol, sorbitol, maltose, glucose, polysaccharide, sucrose, xylitol, mannitol, propylene glycol, polyethylene glycol.
其中,該遮光劑係可選自以下所組成之群組:焦糖、氧化鈦、氧化鐵。 Wherein, the sunscreen can be selected from the group consisting of caramel, titanium oxide, and iron oxide.
其中,該膠囊之填充物可為液狀、懸浮狀、糊狀、粉末狀、顆粒狀等。 Among them, the filling of the capsule can be liquid, suspension, paste, powder, granule, etc.
為達前述發明目的,本發明提供一正壓膠囊製造方法,係於正壓環境之下填充膠囊,再密封該膠囊,其中保留氣泡於膠囊內,該膠囊成品於一大氣壓環境之下即為正壓膠囊。 In order to achieve the aforementioned purpose of the invention, the present invention provides a positive pressure capsule manufacturing method, which is to fill the capsule under a positive pressure environment, and then seal the capsule, wherein the air bubbles are retained in the capsule, and the finished product of the capsule is positive under the atmospheric pressure environment. Press the capsule.
為達前述發明目的,本發明提供另一正壓膠囊製造方法, 係於低溫環境填充,上述低溫環境係低於25℃,再密封該膠囊,其中保留一氣泡於膠囊內,該膠囊成品於常溫環境之下即為正壓膠囊。 In order to achieve the aforementioned purpose of the invention, the present invention provides another positive pressure capsule manufacturing method, It is filled in a low-temperature environment, and the above-mentioned low-temperature environment is lower than 25° C., and then the capsule is sealed, and a bubble is retained in the capsule. The finished product of the capsule is a positive pressure capsule under a normal temperature environment.
1:膠囊囊體 1: Capsule body
2:膠囊內含正壓氣體或氣泡 2: The capsule contains positive pressure gas or bubbles
3:膠囊囊體接合線 3: Capsule body joint line
4:膠囊囊體接合區 4: Capsule body junction area
5:膠囊內部填充物 5: Filling inside the capsule
第1圖係本發明之正壓膠囊示意圖。 Figure 1 is a schematic diagram of the positive pressure capsule of the present invention.
第2圖係本發明之正壓膠囊另一示意圖。 Figure 2 is another schematic diagram of the positive pressure capsule of the present invention.
第3A圖係本發明之正壓膠囊經服用後於胃中尚未消化時之示意圖。 Figure 3A is a schematic diagram of the positive pressure capsule of the present invention when it has not been digested in the stomach after being taken.
第3B圖係本發明之正壓膠囊經服用後於胃中消化中之示意圖。 Figure 3B is a schematic diagram of the positive pressure capsule of the present invention being digested in the stomach after being taken.
本說明書中所述之所有技術性及科學術語,除非另外有所定義,皆為該所屬領域具有通常技藝者可共同瞭解的意義。本發明係以下面的實施例予以示範闡明,但本發明不受下述實施例所限制。本發明所用之材料皆市售易於取得,下列僅為示例可取得之管道。 All technical and scientific terms described in this specification, unless otherwise defined, have meanings commonly understood by those skilled in the art. The present invention is illustrated by the following examples, but the present invention is not limited by the following examples. The materials used in the present invention are all commercially available and easy to obtain. The following are only examples of available pipelines.
本發明之目的係提供一正壓膠囊的製造方法,該方法包括下列步驟:步驟1,將填充膠囊之環境置於正壓環境或低溫環境;步驟2,將填充物填充置膠囊內,且保留內部具有氣泡之空間;步驟3,密封膠囊囊體,使其表面無任何開口,避免氣體外洩。
The object of the present invention is to provide a method for manufacturing a positive pressure capsule. The method includes the following steps: Step 1, placing the environment for filling the capsule in a positive pressure environment or a low temperature environment;
關於前述之正壓環境,係指大於一大氣壓之環境,而一大氣壓即等同於國際單位制1atm、1013hPa、或76cm-Hg。 Regarding the aforementioned positive pressure environment, it refers to an environment greater than one atmosphere, and one atmosphere is equivalent to 1atm, 1013hPa, or 76cm-Hg in the International System of Units.
關於前述之氣泡,該氣泡以不影響投藥劑量為原則,並無 需特別限定氣泡大小;該氣體可為不影響填充物之氣體。 Regarding the aforementioned bubbles, the bubble is based on the principle that it does not affect the dosage of the drug, and there is no The bubble size needs to be specially limited; the gas can be a gas that does not affect the filling.
關於前述之低溫環境,係低於25℃。 Regarding the aforementioned low temperature environment, it is lower than 25°C.
關於前述之正壓膠囊,其形狀可為球型、橢圓型、長橢圓型、試管型、角型等;其尺寸雖無特別限定,即可將填充物量調整至約1毫克至10克的範圍即可。 Regarding the aforementioned positive pressure capsule, its shape can be spherical, oval, oblong, test tube, angular, etc.; although its size is not particularly limited, the amount of filling can be adjusted to the range of about 1 mg to 10 g That's it.
本發明之膠囊原料係為一種即使乾燥後,仍具有可逆性凝膠(reversible gelling)之性質的物質。該物質,例如由HPMC、明膠、洋菜、澱粉、藻酸、瓜爾膠(guar gum)等膠內物質所形成,係以包含有明膠或HPMC、與可塑劑者來做為膠囊之原料較佳。此外,膠囊原料係可因應需要而包含有遮光劑等添加劑。 The raw material of the capsule of the present invention is a substance that still has the properties of reversible gelling even after drying. This substance, for example, is formed of HPMC, gelatin, agar, starch, alginic acid, guar gum and other gum substances. It is made of gelatin or HPMC, and plasticizers as the raw material of the capsule. good. In addition, the capsule raw material system may contain additives such as sunscreens as needed.
關於前述明膠,係可使用由牛、豬等動物所獲取、將膠原蛋白經水解萃取出,而得之明膠。並且,作為具有前述之可逆性凝膠性質的明膠,係包括鹼處理、酸處理、或化學修飾(chemical modification)明膠等。酸處理明膠係為水解劑使用鹽酸或硫酸等酸者;鹼處理明膠係為水解劑使用石灰等鹼類;化學修飾明膠係為將明膠之胺基與琥珀酸(succinic acid)或鄰苯二甲酸(phthalic acid)等有機酸反應所得者。 Regarding the aforementioned gelatin, it is possible to use gelatin obtained from animals such as cattle, pigs, and hydrolyzed and extracted collagen. In addition, gelatin having the aforementioned reversible gel properties includes alkali treatment, acid treatment, or chemical modification (chemical modification) gelatin. Acid-treated gelatin is the hydrolyzing agent using hydrochloric acid or sulfuric acid; alkali-treated gelatin is the hydrolyzing agent using alkalis such as lime; chemically modified gelatin is the combination of the amine group of the gelatin and succinic acid or phthalic acid (phthalic acid) and other organic acid reaction.
關於前述可塑劑,可包含但不受限於甘油、山梨糖醇、麥芽糖、葡萄糖、多糖、蔗糖、木糖醇、甘露糖醇、丙二醇、聚乙二醇等。 Regarding the aforementioned plasticizer, it may include, but is not limited to, glycerol, sorbitol, maltose, glucose, polysaccharides, sucrose, xylitol, mannitol, propylene glycol, polyethylene glycol, and the like.
關於前述遮光劑,可包含但不受限於焦糖、氧化鈦、氧化鐵等。 Regarding the aforementioned sunscreen, it may include, but is not limited to, caramel, titanium oxide, iron oxide, and the like.
本發明適用膠囊填充物之型態不限定,可為液狀、懸浮狀、糊狀、粉末狀、顆粒狀等。 The form of the capsule filling material suitable for the present invention is not limited, and can be liquid, suspension, paste, powder, granular, etc.
本發明之硬膠囊之厚度僅需可發揮膠囊之機能即可,並無特別限制,但以0.01-5毫米(mm)厚度為佳,較佳厚度為0.05-1mm。 The thickness of the hard capsule of the present invention only needs to be able to perform the function of the capsule, and is not particularly limited, but the thickness is preferably 0.01 to 5 millimeters (mm), and the thickness is preferably 0.05 to 1 mm.
本發明之膠囊可用於醫藥品、準醫藥品、食品、化妝品等用途,可依照填充物之組成而定。 The capsule of the present invention can be used for pharmaceuticals, quasi-drugs, foods, cosmetics, etc., depending on the composition of the filling.
關於前述填充物可為醫藥品、準醫藥品,充填於本發明之膠囊之藥效成分若為不損及膠囊機能者即可,無特殊限定。藥品類包括但不限於以下列舉之維生素類、解熱劑、鎮痛劑、消炎劑、抗潰瘍劑、強心劑、抗凝固劑、止血劑、抗骨質再吸收劑、抑制血管新生劑、抗鬱劑、抗腫瘤劑、鎮咳止痰劑、筋遲緩劑、抗癲癇劑、抗過敏劑、心律不整治療劑、血管擴張劑、降壓利尿劑、糖尿病治療劑、抗結核劑、荷爾蒙製劑、止痛劑、抗細菌劑、抗真菌劑及抗病毒劑等,但並非限定於前述之藥理作用群,包含所有對水相對溶解性較差之藥效成分均為本發明硬膠囊之對象。宜為難溶解性之活性物質。 Regarding the aforementioned filler, it may be a medicine or a quasi-drug, and the medicinal ingredient filled in the capsule of the present invention is not particularly limited as long as it does not impair the function of the capsule. Drugs include, but are not limited to, vitamins, antipyretics, analgesics, anti-inflammatory agents, antiulcer agents, cardiotonic agents, anticoagulants, hemostatic agents, anti-bone resorption agents, angiogenesis inhibitors, antidepressants, anti-inflammatory agents, etc. Tumor agents, antitussives and sputum agents, muscle retardants, antiepileptic agents, antiallergic agents, arrhythmia therapeutics, vasodilators, antihypertensive diuretics, diabetes therapeutics, antituberculosis agents, hormonal agents, analgesics, and antibacterial agents Drugs, antifungal agents, antiviral agents, etc., but are not limited to the aforementioned pharmacological action groups, and all medicinal ingredients with relatively poor water solubility are the objects of the hard capsule of the present invention. It is suitable for active substances that are difficult to dissolve.
茲配合第1圖、第2圖之正壓膠囊示意圖將本發明較佳之實施例詳細說明如下: In conjunction with the schematic diagrams of the positive pressure capsules shown in Figures 1 and 2, the preferred embodiments of the present invention are described in detail as follows:
本發明所提供之正壓膠囊製造方法係包含下列步驟:步驟1:將填充膠囊環境置於正壓條件之下,該正壓條件需大於1大氣壓;步驟2:於正壓環境之下,將填充物(5)填充於膠囊內部;步驟3:密封膠囊囊體(1),使其表面無任何開口,避免氣體外洩,但於其中保留氣泡(2); 步驟4:將膠囊成品返還正常環境即一大氣壓之下,膠囊內部即可大於一大氣壓,而成為正壓膠囊。 The method for manufacturing positive pressure capsules provided by the present invention includes the following steps: Step 1: Place the filled capsule environment under a positive pressure condition, the positive pressure condition needs to be greater than 1 atmosphere; Step 2: Under a positive pressure environment, Filler (5) is filled inside the capsule; Step 3: Seal the capsule body (1) so that there are no openings on the surface to avoid gas leakage, but air bubbles (2) are retained in it; Step 4: Return the finished capsule to the normal environment, that is, under one atmospheric pressure, and the inside of the capsule can be greater than one atmospheric pressure and become a positive pressure capsule.
前述該正壓膠囊,於密封膠囊囊體(1)之前或是同時,可另注入氣體,使其中氣室為注入之氣體(2),再將其密封。 In the aforementioned positive pressure capsule, before or at the same time as the capsule body (1) is sealed, another gas can be injected so that the gas chamber is the injected gas (2), and then it is sealed.
該正壓膠囊,經服用者服用之後,進入胃部消化時,當膠囊崩解至一定程度時,其中正壓足以突破膠囊形成破口時,即可達到釋放填充物(5)之目的(第3A圖、第3B圖)。 The positive pressure capsule, after being taken by the user, enters the stomach for digestion, and when the capsule disintegrates to a certain extent, when the positive pressure is sufficient to break through the capsule to form a rupture, the purpose of releasing the filler (5) can be achieved (section 5) 3A, 3B).
本發明所提供之正壓膠囊製造方法係包含下列步驟:步驟1:將填充膠囊環境置於低溫條件之下,該低溫條件需低於25℃;步驟2:於低溫環境之下,將填充物(5)填充於膠囊內部;步驟3:密封膠囊囊體(1),使其表面無任何開口,避免氣體外洩,但於其中保留氣泡(2);步驟4:將膠囊成品返還正常環境即室溫之下,膠囊內部即可大於一大氣壓,而成為正壓膠囊。 The method for manufacturing positive pressure capsules provided by the present invention includes the following steps: Step 1: Place the filled capsule environment under a low temperature condition, which needs to be lower than 25°C; Step 2: Put the filling under a low temperature environment (5) Fill the inside of the capsule; Step 3: Seal the capsule body (1) so that there are no openings on the surface to avoid gas leakage, but retain air bubbles (2); Step 4: Return the finished capsule to the normal environment At room temperature, the inside of the capsule can be greater than one atmosphere and become a positive pressure capsule.
前述該正壓膠囊,於密封膠囊囊體(1)時,可另注入氣體,使其中氣室為注入之氣體(2),再將其密封。 In the aforementioned positive pressure capsule, when the capsule body (1) is sealed, another gas can be injected so that the air chamber is the injected gas (2), and then it is sealed.
該正壓膠囊,經服用者服用之後,進入胃部消化時,膠囊內壓力因體溫而進一步增壓,當膠囊崩解至一定程度時,其中正壓足以突破膠囊形成破口時,即可達到釋放填充物(5)之目的(第3A圖、第3B圖)。 The positive pressure capsule, after being taken by the user, when it enters the stomach for digestion, the pressure in the capsule is further pressurized due to body temperature. When the capsule disintegrates to a certain degree, the positive pressure is enough to break through the capsule to form a breach. The purpose of releasing the filler (5) (Figure 3A, Figure 3B).
本膠囊係為密封之膠囊,該膠囊須為密合囊體(1),膠囊密 合之接合方式可為第1圖所示之膠囊囊體接合線(3)或第2圖所示之膠囊囊體接合區(4),該接合區係囊體一部份融解之後形成密合區域,但本案實施不受限於接合成為密封膠囊之方式,示意圖之目的僅為說明本發明之正壓膠囊須為密合之膠囊。 This capsule is a sealed capsule, and the capsule must be a tightly sealed body (1). The bonding method can be the capsule body joint line (3) shown in Fig. 1 or the capsule body joint area (4) shown in Fig. 2. The joint area is formed after a part of the capsule is melted. However, the implementation of this case is not limited to the way of joining into a sealed capsule. The purpose of the schematic diagram is only to illustrate that the positive pressure capsule of the present invention must be a tightly sealed capsule.
上列詳細說明係針對本發明之可行實施例之具體說明,惟該實施例並非用以限制本發明之專利範圍,凡未脫離本發明技藝精神所為之等效實施或變更,均應包含於本案之專利範圍中。 The above detailed description is a specific description of the possible embodiments of the present invention, but the embodiment is not intended to limit the scope of the patent of the present invention. Any equivalent implementation or modification that does not deviate from the technical spirit of the present invention should be included in this case. In the scope of the patent.
上述多項功效,實屬充分符合新穎性及進步性之法定發明專利要件,爰依法提出申請,懇請 貴局核准本件發明專利申請案,以勵發明。 The above-mentioned multiple functions are in fact fully in line with the statutory requirements for invention patents for novelty and advancement. You file an application in accordance with the law, and I implore your bureau to approve this invention patent application to encourage invention.
1:膠囊囊體 1: Capsule body
2:膠囊內含正壓氣體或氣泡 2: The capsule contains positive pressure gas or bubbles
3:膠囊囊體接合線 3: Capsule body joint line
5:膠囊內部填充之填充物 5: Filling material inside the capsule
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104125059A TWI718100B (en) | 2015-08-03 | 2015-08-03 | Positive pressure capsule and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104125059A TWI718100B (en) | 2015-08-03 | 2015-08-03 | Positive pressure capsule and manufacturing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201705931A TW201705931A (en) | 2017-02-16 |
| TWI718100B true TWI718100B (en) | 2021-02-11 |
Family
ID=58609265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104125059A TWI718100B (en) | 2015-08-03 | 2015-08-03 | Positive pressure capsule and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI718100B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111956625A (en) * | 2020-08-17 | 2020-11-20 | 江苏大地动物保健品有限公司 | An edible veterinary drug for livestock breeding for treating diarrhea |
-
2015
- 2015-08-03 TW TW104125059A patent/TWI718100B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW201705931A (en) | 2017-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI405592B (en) | Non-gelatin soft capsule system | |
| WO1995020380A1 (en) | Intraorally soluble compressed molding and process for producing the same | |
| WO2005079384A2 (en) | Expandable gastric retention device | |
| JP2006016372A (en) | Enteric hard capsule | |
| EP0616802B1 (en) | Oral preparation for release in lower digestive tracts | |
| NZ531461A (en) | Expandable gastric retention device | |
| CN106619128B (en) | sealing composition for capsules and sealing method thereof | |
| CN103263402A (en) | Water-drinking-free oral drug composition and preparation method thereof | |
| CN102164586B (en) | Oral preparation | |
| CN106466303A (en) | Malleation capsule and its manufacture method | |
| TWI718100B (en) | Positive pressure capsule and manufacturing method thereof | |
| CN205215764U (en) | Malleation capsule | |
| CN105012276A (en) | Imidafenacin oral fast dissolving film and preparation method and application thereof | |
| US10729619B2 (en) | Capsule sealing composition and its sealing method thereof | |
| TWM511327U (en) | Positive pressure capsule | |
| JP3122478B2 (en) | Lower gastrointestinal release oral formulation | |
| US20170056319A1 (en) | Positive pressure capsules and method of manufacturing the same | |
| WO2017035747A1 (en) | Positive pressure capsules and method of manufacturing the same | |
| CN101011385A (en) | Pharmaceutical composition of coumarin derivative and its preparation and application | |
| CN104958264B (en) | A kind of gastric floating slow-release micropill for carrying oxymatrine solid dispersions and preparation method thereof | |
| Stegemann | Non-Gelatin-Based Capsules | |
| JP2018199630A (en) | Gastroretentive tablets | |
| CA3213149A1 (en) | A method for the production of gastroretentive compact matrices for the controlled release of active substances and compact matrices thus obtained | |
| CN104013602A (en) | Olanzapine oral instant film and preparation method thereof | |
| US20180256671A1 (en) | Hard Capsule Shell Compositions for the Treatment of Irritable Bowel Syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |